USD 7.37
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| RGNX | 3.1 | -0.4 | -5.1 | -33.6 | -42.6 | -46.5 | -72.0 | -84.1 | -75.8 | -75.8 |
| S&P 500 | 1.0 | 3.7 | 2.1 | 2.3 | 8.2 | 25.4 | 31.0 | 80.6 | 196.5 | 33856.2 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | RGNX |
| name | REGENXBIO Inc. |
| price | 7.37 |
| changes percentage | 3.0769 |
| change | 0.22 |
| day low | 7.1825 |
| day high | 7.435 |
| year high | 28.8 |
| year low | 6.56 |
| market cap | 365147387 |
| price avg 50 | 8.8906 |
| price avg 200 | 12.08355 |
| exchange | NASDAQ |
| volume | 658893 |
| avg volume | 1265447 |
| open | 7.27 |
| previous close | 7.15 |
| eps | -5.01 |
| pe | -1.47 |
| earnings announcement | 2025-02-25T10:59:00.000+0000 |
| shares outstanding | 49545100 |
| timestamp | 2025-01-17 21:00:00 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001590877 | |||
| revenue | 90242000 | 112724000 | -19.94 |
| gross profit | 53029000 | 58179000 | -8.85 |
| gross profit ratio | 0.59 | 0.52 | 13.86 |
| research and development expenses | 232266000 | 242453000 | -4.20 |
| operating expenses | 321157000 | 321055000 | 0.03 |
| interest income | 25000 | 342000 | -92.69 |
| interest expense | 6862000 | 23254000 | -70.49 |
| ebitda | -239464000 | -244242000 | 1.96 |
| ebitdaratio | -2.65 | -2.33 | -13.94 |
| operating income | -268128000 | -262876000 | -2.00 |
| operating income ratio | -2.97 | -2.33 | -27.41 |
| net income | -263494000 | -280321000 | 6.00 |
| net income ratio | -2.92 | -2.49 | -17.41 |
| eps | -6.02 | -6.5 | 7.38 |
Revenue Growth: revenue increased to 90 million in 2023 from 113 million in 2022 representing a change of -19.94%. This indicates a sales growth, which is a positive sign for the company.
Operating Income: Operating income increased to -268 million in 2023 from -263 million in 2022 representing a change of -2.0%. The increase in operating income indicates better operational performance and increased profitability.
Earnings per Share (EPS): EPS increased to -6.02 in 2023 from -6.02 in 2022 representing a change of 7.38%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Gross Profit: Gross Profit decreased to 53 million in 2023 from 58 million in 2022 representing a change of -8.85%. This indicates a sales profitability decline, which is a negative sign for the company.
Research and Development (R&D) Expenses: R&D Expenses decreased to 232 million in 2023 from 242 million in 2022 representing a change of -4.2%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 321 million in 2023 from 321 million in 2022 representing a change of 0.03%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -239 million in 2023 from -244 million in 2022 representing a change of 1.96%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Net Income: Net income decreased to -263 million in 2023 from -280 million in 2022 representing a change of 6.0%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001590877 | |||
| revenue | 24197000 | 22295000 | 8.53 |
| gross profit | 11810000 | 7665000 | 54.08 |
| gross profit ratio | 0.49 | 0.34 | 41.97 |
| research and development expenses | 54429000 | 44818000 | 21.44 |
| operating expenses | 73888000 | 63702000 | 15.99 |
| interest income | 25000 | 29000 | -13.79 |
| interest expense | 820000 | 449000 | 82.63 |
| ebitda | -54816000 | -48489000 | -13.05 |
| ebitdaratio | -2.27 | -2.33 | 2.84 |
| operating income | -62078000 | -56037000 | -10.78 |
| operating income ratio | -2.57 | -2.51 | -2.07 |
| net income | -59597000 | -52989000 | -12.47 |
| net income ratio | -2.46 | -2.38 | -3.63 |
| eps | -1.17 | -1.05 | -11.43 |
Revenue Growth: revenue increased to 24 million in 2024Q3 from 22 million in 2024Q2 representing a change of 8.53%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 12 million in 2024Q3 from 8 million in 2024Q2 representing a change of 54.08%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 54 million in 2024Q3 from 45 million in 2024Q2 representing a change of 21.44%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -55 million in 2024Q3 from -48 million in 2024Q2 representing a change of -13.05%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -62 million in 2024Q3 from -56 million in 2024Q2 representing a change of -10.78%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -60 million in 2024Q3 from -53 million in 2024Q2 representing a change of -12.47%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Operating Expenses: Operating Expenses increased to 74 million in 2024Q3 from 64 million in 2024Q2 representing a change of 15.99%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Earnings per Share (EPS): EPS increased to -1.17 in 2024Q3 from -1.17 in 2024Q2 representing a change of -11.43%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001590877 | |||
| total assets | 573970000 | 833268000 | -31.12 |
| total liabilities | 262228000 | 317073000 | -17.30 |
| total equity | 311742000 | 516195000 | -39.61 |
| cash and cash equivalents | 34522000 | 96952000 | -64.39 |
| short term investments | 240736000 | 267690000 | -10.07 |
| long term investments | 38871000 | 200560000 | -80.62 |
| total current assets | 334971000 | 415976000 | -19.47 |
| total non current assets | 238999000 | 417292000 | -42.73 |
| total current liabilities | 130271999 | 130434000 | -0.12 |
| total non current liabilities | 131956000 | 186639000 | -29.30 |
| common stock | 4000 | 4000 | 0.00 |
| retained earnings | -705047000 | -441553000 | -59.67 |
| total debt | 89290000 | 94799000 | -5.81 |
Total Assets: Total Assets decreased to 574 million in 2023 from 833 million in 2022 representing a change of -31.12%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 312 million in 2023 from 516 million in 2022 representing a change of -39.61%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 35 million in 2023 from 97 million in 2022 representing a change of -64.39%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 241 million in 2023 from 268 million in 2022 representing a change of -10.07%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 335 million in 2023 from 416 million in 2022 representing a change of -19.47%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -705 million in 2023 from -442 million in 2022 representing a change of -59.67%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 262 million in 2023 from 317 million in 2022 representing a change of -17.3%. This indicates a decrease in overall liabilities.
Total Current Liabilities: Total Current Liabilities decreased to 130 million in 2023 from 130 million in 2022 representing a change of -0.12%. This indicates a lower short-term debt burden.
Total Debt: Total Debt decreased to 89 million in 2023 from 95 million in 2022 representing a change of -5.81%. This indicates a reduction in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001590877 | |||
| total assets | 519114000 | 569379000 | -8.83 |
| total liabilities | 217698000 | 221112000 | -1.54 |
| total equity | 301416000 | 348267000 | -13.45 |
| cash and cash equivalents | 56617000 | 57765000 | -1.99 |
| short term investments | 198843000 | 232592000 | -14.51 |
| long term investments | 0 | 39437000 | -100.00 |
| total current assets | 313396000 | 346683000 | -9.60 |
| total non current assets | 205718000 | 222696000 | -7.62 |
| total current liabilities | 102725000 | 98273000 | 4.53 |
| total non current liabilities | 114973000 | 122839000 | -6.40 |
| common stock | 5000 | 5000 | 0.00 |
| retained earnings | -880963000 | -821366000 | -7.26 |
| total debt | 84062000 | 158715000 | -47.04 |
Total Assets: Total Assets decreased to 519 million in 2024Q3 from 569 million in 2024Q2 representing a change of -8.83%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 301 million in 2024Q3 from 348 million in 2024Q2 representing a change of -13.45%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 57 million in 2024Q3 from 58 million in 2024Q2 representing a change of -1.99%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 199 million in 2024Q3 from 233 million in 2024Q2 representing a change of -14.51%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 313 million in 2024Q3 from 347 million in 2024Q2 representing a change of -9.6%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 103 million in 2024Q3 from 98 million in 2024Q2 representing a change of 4.53%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -881 million in 2024Q3 from -821 million in 2024Q2 representing a change of -7.26%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 218 million in 2024Q3 from 221 million in 2024Q2 representing a change of -1.54%. This indicates a decrease in overall liabilities.
Total Debt: Total Debt decreased to 84 million in 2024Q3 from 159 million in 2024Q2 representing a change of -47.04%. This indicates a reduction in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001590877 | |||
| net change in cash | -62430000 | -248257000 | 74.85 |
| operating cash flow | -218407000 | -207488000 | -5.26 |
| free cash flow | -228367000 | -238212000 | 4.13 |
| capital expenditure | -9960000 | -30724000 | 67.58 |
| depreciation and amortization | 17320000 | 12909000 | 34.17 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 40267000 | 40788000 | -1.28 |
| accounts payables | -2791000 | 18790000 | -114.85 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -9960000 | -30724000 | 67.58 |
| net cash used for investing activites | 190943000 | -11929000 | 1700.66 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 6700000 | 1742000 | 284.62 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -34966000 | -28840000 | -21.24 |
| cash at end of period | 36552000 | 98982000 | -63.07 |
| accounts receivables | 3935000 | 4822000 | -18.39 |
| cash at beginning of period | 98982000 | 347239000 | -71.49 |
Net Change in Cash: Net Change in Cash increased to -62 million in 2023 from -248 million in 2022 representing a change of 74.85%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Free Cash Flow: Free Cash Flow increased to -228 million in 2023 from -238 million in 2022 representing a change of 4.13%. This indicates an increase in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation decreased to 40 million in 2023 from 41 million in 2022 representing a change of -1.28%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables decreased to 3 million in 2023 from 19 million in 2022 representing a change of -114.85%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables decreased to 4 million in 2023 from 5 million in 2022 representing a change of -18.39%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Operating Cash Flow: Operating Cash Flow decreased to -218 million in 2023 from -207 million in 2022 representing a change of -5.26%. This indicates that the company generated less cash from its core business operations.
Capital Expenditure: Capital Expenditure increased to -10 million in 2023 from -31 million in 2022 representing a change of 67.58%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001590877 | |||
| operating cash flow | -40549000 | -45497000 | 10.88 |
| free cash flow | -40875000 | -45971000 | 11.09 |
| capital expenditure | -326000 | -474000 | 31.22 |
| depreciation and amortization | 3961000 | 4051000 | -2.22 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 9884000 | 9435000 | 4.76 |
| accounts receivables | -710000 | -6893000 | 89.70 |
| accounts payables | 3124000 | -14915000 | 120.95 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -326000 | -474000 | 31.22 |
| net cash used for investing activites | 50258000 | -268000 | 18852.99 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 246000 | -160000 | 253.75 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -10857000 | -9445000 | -14.95 |
| net change in cash | 882000 | -55210000 | 101.60 |
| cash at end of period | 58647000 | 57765000 | 1.53 |
| cash at beginning of period | 57765000 | 112975000 | -48.87 |
Net Change in Cash: Net Change in Cash increased to 1 million in 2024Q3 from -55 million in 2024Q2 representing a change of 101.6%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to -41 million in 2024Q3 from -45 million in 2024Q2 representing a change of 10.88%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -41 million in 2024Q3 from -46 million in 2024Q2 representing a change of 11.09%. This indicates an increase in cash generated after accounting for capital expenditures.
Accounts Payables: The absolute value of Accounts Payables decreased to 3 million in 2024Q3 from 15 million in 2024Q2 representing a change of 120.95%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Capital Expenditure: Capital Expenditure increased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of 31.22%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Stock-Based Compensation: Stock-Based Compensation increased to 10 million in 2024Q3 from 9 million in 2024Q2 representing a change of 4.76%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Receivables: Accounts Receivables increased to -1 in 2024Q3 from -7 million in 2024Q2 representing a change of 89.7%. This suggests that the company is less capable of collecting payments from its customers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 2.06 | 2.61 | -21.01 |
| net income per share | -6.02 | -6.5 | 7.25 |
| operating cash flow per share | -4.99 | -4.81 | -3.86 |
| free cash flow per share | -5.22 | -5.52 | 5.41 |
| cash per share | 6.29 | 8.45 | -25.52 |
| book value per share | 7.13 | 11.96 | -40.41 |
| tangible book value per share | 7.13 | 11.96 | -40.41 |
| shareholders equity per share | 7.13 | 11.96 | -40.41 |
| interest debt per share | 2.2 | 2.74 | -19.64 |
| market cap | 785025300 | 978687360 | -19.79 |
| enterprise value | 839793300 | 976534360 | -14.00 |
| pe ratio | -2.98 | -3.49 | 14.67 |
| price to sales ratio | 8.7 | 8.68 | 0.20 |
| pocfratio | -3.59 | -4.72 | 23.80 |
| pfcf ratio | -3.44 | -4.11 | 16.33 |
| pb ratio | 2.52 | 1.9 | 32.82 |
| ptb ratio | 2.52 | 1.9 | 32.82 |
| ev to sales | 9.31 | 8.66 | 7.42 |
| enterprise value over ebitda | -3.51 | -4.0 | 12.29 |
| ev to operating cash flow | -3.85 | -4.71 | 18.30 |
| ev to free cash flow | -3.68 | -4.1 | 10.30 |
| earnings yield | -0.34 | -0.29 | -17.19 |
| free cash flow yield | -0.29 | -0.24 | -19.52 |
| debt to equity | 0.29 | 0.18 | 55.96 |
| debt to assets | 0.16 | 0.11 | 36.74 |
| net debt to ebitda | -0.23 | 0.01 | -2694.56 |
| current ratio | 2.57 | 3.19 | -19.37 |
| interest coverage | -39.07 | -11.3 | -245.65 |
| income quality | 0.83 | 0.74 | 11.98 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.98 | 0.76 | 29.62 |
| research and ddevelopement to revenue | 2.57 | 2.15 | 19.66 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.05 | -0.15 | 69.20 |
| capex to revenue | 0.11 | 0.27 | -59.51 |
| capex to depreciation | 0.58 | 2.38 | -75.84 |
| stock based compensation to revenue | 0.45 | 0.36 | 23.32 |
| graham number | 31.09 | 41.81 | -25.66 |
| roic | -0.59 | -0.37 | -61.70 |
| return on tangible assets | -0.46 | -0.34 | -36.46 |
| graham net net | 0.75 | 1.75 | -57.20 |
| working capital | 204699001 | 285542000 | -28.31 |
| tangible asset value | 311742000 | 516195000 | -39.61 |
| net current asset value | 72743000 | 98903000 | -26.45 |
| invested capital | 397289001 | 492343000 | -19.31 |
| average receivables | 27211500 | 30260500 | -10.08 |
| average payables | 24999500 | 19300000 | 29.53 |
| average inventory | 6950000 | 16326000 | -57.43 |
| days sales outstanding | 106.54 | 90.93 | 17.17 |
| days payables outstanding | 223.49 | 182.1 | 22.73 |
| days of inventory on hand | 0 | 93.01 | -100.00 |
| receivables turnover | 3.43 | 4.01 | -14.65 |
| payables turnover | 1.63 | 2.0 | -18.52 |
| inventory turnover | 0 | 3.92 | -100.00 |
| roe | -0.85 | -0.54 | -55.64 |
| capex per share | 0.23 | 0.71 | -68.01 |
ROE: Return on Equity (ROE) decreased to -0.85 on 2023-12-31 from -0.54 on 2022-12-31, representing a change of -55.64%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -2.98 on 2023-12-31 from -3.49 on 2022-12-31, representing a change of 14.67%. Indicating an increase in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 2.57 on 2023-12-31 from 3.19 on 2022-12-31, representing a change of -19.37%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. However, it is still above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.29 on 2023-12-31 from 0.18 on 2022-12-31, representing a change of 55.96%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| RGNX | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0.48 | 0.44 | 8.11 |
| net income per share | -1.17 | -1.05 | -12.03 |
| operating cash flow per share | -0.8 | -0.9 | 11.22 |
| free cash flow per share | -0.8 | -0.91 | 11.43 |
| cash per share | 5.03 | 5.74 | -12.36 |
| book value per share | 5.93 | 6.88 | -13.79 |
| tangible book value per share | 5.93 | 6.88 | -13.79 |
| shareholders equity per share | 5.93 | 6.88 | -13.79 |
| interest debt per share | 1.67 | 3.15 | -46.88 |
| market cap | 532892000 | 560153070 | -4.87 |
| enterprise value | 560337000 | 661103070 | -15.24 |
| pe ratio | -2.24 | -2.64 | 15.41 |
| price to sales ratio | 22.02 | 25.12 | -12.34 |
| pocfratio | -13.14 | -12.31 | -6.74 |
| pfcf ratio | -13.04 | -12.18 | -6.99 |
| pb ratio | 1.77 | 1.61 | 9.92 |
| ptb ratio | 1.77 | 1.61 | 9.92 |
| ev to sales | 23.16 | 29.65 | -21.90 |
| enterprise value over ebitda | -10.22 | -13.63 | 25.03 |
| ev to operating cash flow | -13.82 | -14.53 | 4.90 |
| ev to free cash flow | -13.71 | -14.38 | 4.68 |
| earnings yield | -0.11 | -0.09 | -18.22 |
| free cash flow yield | -0.08 | -0.08 | 6.54 |
| debt to equity | 0.28 | 0.46 | -38.80 |
| debt to assets | 0.16 | 0.28 | -41.91 |
| net debt to ebitda | -0.5 | -2.08 | 75.95 |
| current ratio | 3.05 | 3.53 | -13.52 |
| interest coverage | -75.7 | -124.8 | 39.34 |
| income quality | 0.68 | 0.86 | -20.76 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.8 | 0.85 | -5.09 |
| research and ddevelopement to revenue | 2.25 | 2.01 | 11.90 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.01 | -0.01 | 22.83 |
| capex to revenue | 0.01 | 0.02 | -36.63 |
| capex to depreciation | 0.08 | 0.12 | -29.66 |
| stock based compensation to revenue | 0.41 | 0.42 | -3.48 |
| graham number | 12.51 | 12.73 | -1.73 |
| roic | -0.15 | -0.11 | -33.35 |
| return on tangible assets | -0.11 | -0.09 | -23.36 |
| graham net net | 1.12 | 1.73 | -35.43 |
| working capital | 210671000 | 248410000 | -15.19 |
| tangible asset value | 301416000 | 348267000 | -13.45 |
| net current asset value | 95698000 | 125571000 | -23.79 |
| invested capital | 386515000 | 428723000 | -9.85 |
| average receivables | 24689000 | 20761000 | 18.92 |
| average payables | 17941999.5 | 23858999.5 | -24.80 |
| average inventory | 0 | 0.5 | -100.00 |
| days sales outstanding | 93.66 | 97.67 | -4.11 |
| days payables outstanding | 141.84 | 100.65 | 40.92 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0.96 | 0.92 | 4.28 |
| payables turnover | 0.63 | 0.89 | -29.04 |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.2 | -0.15 | -29.95 |
| capex per share | 0.01 | 0.01 | -31.49 |
ROE: Return on Equity (ROE) decreased to -0.20 on 2024-09-30 Q3 from -0.15 on 2024-06-30 Q2, representing a change of -29.95%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio decreased to 3.05 on 2024-09-30 Q3 from 3.53 on 2024-06-30 Q2, representing a change of -13.52%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -2.24 on 2024-09-30 Q3 from -2.64 on 2024-06-30 Q2, representing a change of 15.41%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.28 on 2024-09-30 Q3 from 0.46 on 2024-06-30 Q2, representing a change of -38.80%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2025-01-16 04:01:10
Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025. Partnership established with Nippon Shinyaku to develop RGX-121 and RGX-111 for the treatment of patients with MPS II and MPS I respectively. Data from both the ASCENT and ATMOSPHERE pivotal studies, using ABBV-RGX-314 for the treatment of patients with Wet Age-Related Macular Degeneration, expected in 2026.
Sentiment: Positive
Publish Date: 2025-01-15 15:27:58
Regenxbio Inc. remains undervalued despite its cutting-edge AAV gene therapy technology and promising assets like RGX-314 for wet AMD and RGX-121 for MPS II. RGX-314, partnered with AbbVie, targets wet AMD with global regulatory submissions expected in H1 2026; RGX-121 has a rolling BLA submission expected to complete in Q1 2025. Financially, RGNX has a market cap of $344mn and a cash balance of $279mn, bolstered by a recent $110mn upfront fee from Nippon Shinyaku.
Sentiment: Positive
Publish Date: 2025-01-14 05:00:00
REGENXBIO to receive $110 million upfront, potential milestone payments of up to $700 million and meaningful double-digit royalties on net sales, and lead manufacturing Nippon Shinyaku to lead commercialization of first potential gene therapies for Mucopolysaccharidosis II (MPS II) and Mucopolysaccharidosis I (MPS I) in U.S. and Asia REGENXBIO retains rights to RGX-121 Priority Review Voucher (PRV) with potential accelerated approval expected in 2025; rolling BLA submission underway ROCKVILLE, Md. , Jan. 14, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) and Nippon Shinyaku Co., Ltd.
Sentiment: Neutral
Publish Date: 2025-01-13 08:31:00
Pivotal data evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with wet age-related macular degeneration (wet AMD) are expected in 2026 AbbVie and REGENXBIO will plan the Phase 3 clinical program of investigational ABBV-RGX-314 in diabetic retinopathy (DR) NORTH CHICAGO, Ill. and ROCKVILLE, Md.
Sentiment: Positive
Publish Date: 2024-12-06 18:29:00
NEW YORK , Dec. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range.
Sentiment: Positive
Publish Date: 2024-11-18 07:05:00
Alignment achieved with FDA on AFFINITY DUCHENNE® pivotal program and access to accelerated approval; BLA expected in 2026 Pivotal trial of RGX-202 is enrolling ambulatory patients aged 1 and above with first patient dosed Phase I/II data show RGX-202 recipients exceeding external natural history and established benchmarks for clinical outcomes Functional improvements seen in all patients treated with dose level 1 and dose level 2 at 12 and 9 months respectively New biomarker data confirms consistent robust expression of differentiated RGX-202 microdystrophin in the muscle Favorable safety profile observed at both dose levels; no serious adverse events or AEs of special interest Webcast to be held at 8:00 a.m. today ROCKVILLE, Md.
Sentiment: Neutral
Publish Date: 2024-11-14 07:05:00
- Event will feature Aravindhan Veerapandiyan, M.D., principal investigator of the AFFINITY DUCHENNE® trial and Michael Kelly, PhD, Chief Scientific Officer of CureDuchenne ROCKVILLE, Md.
Sentiment: Neutral
Publish Date: 2024-11-06 23:16:13
REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript
Sentiment: Negative
Publish Date: 2024-11-06 19:00:45
Regenxbio (RGNX) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.41 per share a year ago.
Sentiment: Positive
Publish Date: 2024-11-06 16:05:00
Advancement in Phase I/II AFFINITY DUCHENNE® trial of RGX-202 for Duchenne Muscular Dystrophy; pivotal trial initiation and first functional data expected this month BLA submission for RGX-121 initiated and expected to complete in Q1 2025 Positive Phase II data support bilateral administration of subretinal ABBV-RGX-314; data consistent with that from multiple previous studies demonstrating favorable safety and efficacy profile End-of-Phase II meeting for ABBV-RGX-314 in diabetic retinopathy accelerated to Q4 2024 to support global pivotal program initiation in H1 2025 Conference call today at 4:30 p.m. ET ROCKVILLE, Md.
Sentiment: Neutral
Publish Date: 2024-11-04 07:05:00
ROCKVILLE, Md. , Nov. 4, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: UBS Global Healthcare Conference Fireside Chat: Wednesday, November 13 at 12:30 p.m.
Sentiment: Positive
Publish Date: 2024-10-31 15:38:10
Positive updated long-term results from phase I/II/III CAMPSITE study using RGX-121 for the treatment of patients with MPS II. Rolling BLA submission of RGX-121 for the treatment of patients with MPS II expected any day now in Q4 of 2024. The global Hunter Syndrome treatment market is expected to reach $1.78 billion by 2030.
Sentiment: Neutral
Publish Date: 2024-10-30 07:05:00
ROCKVILLE, Md. , Oct. 30, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, November 6, at 4:30 p.m.
Sentiment: Positive
Publish Date: 2024-10-21 07:05:00
97% reduction in treatment burden at nine months after treatment with ABBV-RGX-314 Data consistent with that from multiple previous studies demonstrating favorable safety and efficacy profile Well tolerated with zero cases of intraocular inflammation in a setting of no prophylactic steroids Data highlight the potential of ABBV-RGX-314 to treat both eyes in wet AMD ROCKVILLE, Md. , Oct. 21, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced positive data from the Phase II fellow eye sub-study evaluating the subretinal delivery of ABBV-RGX-314 in patients with bilateral wet age-related macular degeneration (wet AMD).
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
